Interestingly, high GNA13 expression significantly correlated with better survival rates in all breast cancer patients regardless of treatment group, in patients who underwent treatments other than endocrine therapy, in ER+ patients who underwent endocrine therapy (Fig. 1A) and also in ER- patients (Fig. S1A). This evidence concerns the gene ESR1 and breast carcinoma.